Messenger RNA (mRNA) cancer vaccines have progressed rapidly, with personalized platforms such as mRNA-4157 and BNT122 demonstrating feasibility, safety, and durable immune activity but limited scalability. Off-the-shelf constructs, including BNT111 and BNT113, enable faster, broader deployment, yet they risk reduced p...
Seongdong Jeong, Benjamin R. Schrank, James J. Mancuso et al.· Cancer Discovery· 0 citations
The key discoveries that laid the foundations for CAR T cell therapies are summarized and a broad overview of the current principles of CAR design, their clinical development and emerging strategies aimed at enhancing efficacy, broadening indications and achieving durable immune control across disease types are provide...
H. Rafei, R. Upadhyay, Padmanee Sharma· Nature reviews. Immunology· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.